Viking Therapeutics Statistics
Total Valuation
VKTX has a market cap or net worth of $4.71 billion. The enterprise value is $3.78 billion.
Important Dates
The next estimated earnings date is Wednesday, February 5, 2025, after market close.
| Earnings Date | Feb 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
VKTX has 111.44 million shares outstanding. The number of shares has increased by 19.97% in one year.
| Current Share Class | 111.44M |
| Shares Outstanding | 111.44M |
| Shares Change (YoY) | +19.97% |
| Shares Change (QoQ) | +0.47% |
| Owned by Insiders (%) | 2.08% |
| Owned by Institutions (%) | 74.57% |
| Float | 105.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.17 |
| P/TBV Ratio | 5.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 36.47, with a Debt / Equity ratio of 0.00.
| Current Ratio | 36.47 |
| Quick Ratio | 36.23 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,395.50 |
Financial Efficiency
Return on equity (ROE) is -15.50% and return on invested capital (ROIC) is -13.06%.
| Return on Equity (ROE) | -15.50% |
| Return on Assets (ROA) | -12.68% |
| Return on Capital (ROIC) | -13.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.67M |
| Employee Count | 27 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +120.63% in the last 52 weeks. The beta is 0.88, so VKTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.88 |
| 52-Week Price Change | +120.63% |
| 50-Day Moving Average | 57.81 |
| 200-Day Moving Average | 61.71 |
| Relative Strength Index (RSI) | 33.93 |
| Average Volume (20 Days) | 3,817,885 |
Short Selling Information
The latest short interest is 18.07 million, so 16.22% of the outstanding shares have been sold short.
| Short Interest | 18.07M |
| Short Previous Month | 16.99M |
| Short % of Shares Out | 16.22% |
| Short % of Float | 17.14% |
| Short Ratio (days to cover) | 3.20 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -133.97M |
| Pretax Income | -96.75M |
| Net Income | -99.15M |
| EBITDA | n/a |
| EBIT | -133.97M |
| Earnings Per Share (EPS) | -$0.93 |
Full Income StatementBalance Sheet
The company has $930.44 million in cash and $1.24 million in debt, giving a net cash position of $929.21 million or $8.34 per share.
| Cash & Cash Equivalents | 930.44M |
| Total Debt | 1.24M |
| Net Cash | 929.21M |
| Net Cash Per Share | $8.34 |
| Equity (Book Value) | 911.45M |
| Book Value Per Share | 8.18 |
| Working Capital | 910.96M |
Full Balance SheetCash Flow
| Operating Cash Flow | -74.25M |
| Capital Expenditures | n/a |
| Free Cash Flow | -74.25M |
| FCF Per Share | -$0.67 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |